Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.authorMcCallum, Andrew D
dc.contributor.authorSloan, Derek James
dc.date.accessioned2017-11-09T12:30:12Z
dc.date.available2017-11-09T12:30:12Z
dc.date.issued2017-07
dc.identifier.citationMcCallum , A D & Sloan , D J 2017 , ' The importance of clinical pharmacokinetic–pharmacodynamic studies in unraveling the determinants of early and late tuberculosis outcomes ' , International Journal of Pharmacokinetics , vol. 2 , no. 3 , pp. 195-212 . https://doi.org/10.4155/ipk-2017-0004en
dc.identifier.issn2053-0846
dc.identifier.otherPURE: 251504347
dc.identifier.otherPURE UUID: 711e9a61-7f53-47b5-ba42-20dc58b2cc78
dc.identifier.urihttps://hdl.handle.net/10023/12035
dc.description.abstractTuberculosis remains a major infectious cause of morbidity and mortality worldwide. Current antibiotic regimens, constructed prior to the development of modern pharmacokinetic-pharmacodynamic (PK–PD) tools, are based on incomplete understanding of exposure–response relationships in drug susceptible and multidrug resistant tuberculosis. Preclinical and population PK data suggest that clinical PK–PD studies may enable therapeutic drug monitoring for some agents and revised dosingf or others. Future clinical PK–PD challenges include: incorporation of PK methods to assay free concentrations for all active metabolites; selection of appropriate early outcome measures which reflect therapeutic response; elucidation of genetic contributors to interindividual PK variability; conduct of targeted studies on special populations (including children); and measurement of PK–PD parameters at the site of disease.
dc.language.isoeng
dc.relation.ispartofInternational Journal of Pharmacokineticsen
dc.rightsCopyright the Author(s) 2017. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.subjectClinical trialsen
dc.subjectCompartmental pharmacokineticsen
dc.subjectMultidrug-resistant tuberculosisen
dc.subjectPharmacogeneticsen
dc.subjectPharmacokinetics-pharmacodynamicsen
dc.subjectTherapeutic drug monitoringen
dc.subjectTuberculosisen
dc.subjectRM Therapeutics. Pharmacologyen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subject.lccRMen
dc.titleThe importance of clinical pharmacokinetic–pharmacodynamic studies in unraveling the determinants of early and late tuberculosis outcomesen
dc.typeJournal itemen
dc.description.versionPublisher PDFen
dc.contributor.institutionUniversity of St Andrews. School of Medicineen
dc.contributor.institutionUniversity of St Andrews. Infection and Global Health Divisionen
dc.identifier.doihttps://doi.org/10.4155/ipk-2017-0004
dc.description.statusPeer revieweden


This item appears in the following Collection(s)

Show simple item record